Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of PKU
3.2.1.2 Advancements in new therapies for PKU
3.2.1.3 Enhanced newborn screening programs
3.2.1.4 Growing awareness for early screening and treatment
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory requirements
3.3 Growth potential analysis
3.4 Reimbursement scenario
3.5 Pipeline analysis
3.6 Regulatory landscape
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By PKU Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Classic PKU
5.3 Mild PKU
5.4 Moderate or variant PKU
5.5 Hyperphenylalaninemia
Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Drug therapy
6.3 Dietary management
6.4 Other treatment types
Chapter 7 Market Estimates and Forecast, By Age Group, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Pediatrics
7.3 Adults
Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Oral
8.3 Parenteral
Chapter 9 Market Estimates and Forecast, By End-user, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 Hospitals
9.3 Specialty clinics
9.4 Other end-users
Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Netherlands
10.3.7 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 Abbott Laboratories
11.2 American Gene Technologies
11.3 APR Applied Pharma Research s.a.
11.4 BioMarin Pharmaceutical Inc.
11.5 Codexis, Inc.
11.6 Erytech Pharma SA
11.7 Homology Medicines, Inc.
11.8 Lysogene S.A.
11.9 PIAM Farmaceutici S.P.A.
11.10 Pluvia AS
11.11 PTC Therapeutics
11.12 SOM Innovation Biotech SL
11.13 Synlogic
11.14 Ultragenyx (Dimension Therapeutics)
11.15 Vitaflo International Ltd.
